Vertex Reports Positive Results in Phase 1/2 Study of VX-880 for Type 1 Diabetes at ADA2024 in Orlando

Jun 21, 2024, 08:44 PM

Vertex Pharmaceuticals has announced positive results from its ongoing Phase 1/2 study of VX-880, a stem cell-derived therapy for the treatment of type 1 diabetes. The results, presented at the American Diabetes Association's 84th Scientific Sessions in Orlando, reveal that the therapy can lead to insulin independence and decreased hypoglycemic events. Of the ten patients who completed their 180-day check-in, seven are no longer using insulin. Additionally, all 12 patients who received the full dose of VX-880 demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90, with three achieving insulin independence. Katherine Lewin reported on the findings at ADA2024.